Exploratory Phase 2a Randomized, Double-blind, Placebo-controlled Study of Dipraglurant (ADX48621) Immediate Release Tablets in Patients With Blepharospasm
Latest Information Update: 07 Nov 2023
Price :
$35 *
At a glance
- Drugs Dipraglurant (Primary)
- Indications Blepharospasm
- Focus Adverse reactions
- Sponsors Addex Therapeutics
- 27 May 2022 Results published in an Addex Therapeutics Media Release.
- 13 Apr 2022 Status changed from recruiting to active, no longer recruiting, according to an Addex Therapeutics media release.
- 10 Mar 2022 According to an Addex Therapeutics media release, data from the study is expected in Q2 2022.